Analyst Ratings for [PRTA] Prothena Corporation plc

5/28/25	Downgrades	Neutral Underperform	X
PRTA Prothena BofA Securities
$4
5/27/25	Downgrades	Overweight Neutral	X
PRTA Prothena Cantor Fitzgerald
5/27/25	Downgrades	Buy Hold	X
PRTA Prothena Jefferies
$6
5/27/25	Downgrades	Outperform Perform	X
PRTA Prothena Oppenheimer
12/20/24	Initiated	Buy	X
PRTA Prothena Chardan Capital Markets
$40
1/30/24	Downgrades	Buy Neutral	X
PRTA Prothena BofA Securities
$68 $38
12/12/23	Initiated	Buy	X
PRTA Prothena Deutsche Bank
$62
4/24/23	Initiated	Outperform	X
PRTA Prothena SVB Securities
$80
1/27/23	Initiated	Overweight	X
PRTA Prothena Piper Sandler
$94
11/4/22	Downgrades	Outperform Sec Perform	X
PRTA Prothena RBC Capital Mkts
$52 $55
9/28/22	Upgrades	Neutral Buy	X
PRTA Prothena BofA Securities
11/19/21	Initiated	Mkt Outperform	X
PRTA Prothena JMP Securities
$77
6/18/21	Upgrades	Underperform Neutral	X
PRTA Prothena BofA Securities
$12 $49
5/26/21	Initiated	Buy	X
PRTA Prothena Citigroup
$39
2/26/21	Upgrades	Sec Perform Outperform	X
PRTA Prothena RBC Capital Mkts
$14 $28
2/12/21	Upgrades	Hold Buy	X
PRTA Prothena Jefferies
$15 $30
2/2/21	Upgrades	Neutral Buy	X
PRTA Prothena BTIG Research
$29
5/21/18	Downgrades	Eq Weight Underweight	X
PRTA Prothena Barclays
$14 $12
4/5/18	Reiterated	Overweight	X
PRTA Prothena Barclays
$70 $50

PRTA Prothena Corporation plc

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). The Company has generated monoclonal antibodies that selectively bind to amyloidogenic (diseased) forms of the Transthyretin (TTR)-mediated amyloidosis (ATTR) protein. The Company's pipeline also includes late discovery-stage programs for which the Company is testing the efficacy of antibodies in preclinical models of diseases related to amyloid or cell adhesion.